Blueprint Medicines Drug Patent Portfolio

Blueprint Medicines owns 1 orange book drug protected by 7 US patents Given below is the list of Blueprint Medicines's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12060354 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making 08 Mar, 2042
Active
US11964980 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making 10 Apr, 2040
Active
US11999744 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making 10 Apr, 2040
Active
US11827642 Compositions useful for treating disorders related to KIT 15 Oct, 2034
Active
US9200002 Compositions useful for treating disorders related to KIT 15 Oct, 2034
Active
US9944651 Compositions useful for treating disorders related to kit 15 Oct, 2034
Active
US9994575 Compositions useful for treating disorders related to kit 15 Oct, 2034
Active


Given below is the list of recent legal activities going on the following drug patents of Blueprint Medicines.

Activity Date Patent Number
Patent litigations
Electronic Review 07 Jun, 2024 US11964980
Patent eGrant Notification 23 Apr, 2024 US11964980
Email Notification 23 Apr, 2024 US11964980
Mail Patent eGrant Notification 23 Apr, 2024 US11964980
Recordation of Patent Grant Mailed 23 Apr, 2024 US11964980
Patent Issue Date Used in PTA Calculation 23 Apr, 2024 US11964980
Recordation of Patent eGrant 23 Apr, 2024 US11964980
Email Notification 04 Apr, 2024 US11964980
Issue Notification Mailed 03 Apr, 2024 US11964980
Filing Receipt - Replacement 21 Mar, 2024 US11964980
Email Notification 21 Mar, 2024 US11964980
Dispatch to FDC 20 Mar, 2024 US11964980
Application Is Considered Ready for Issue 20 Mar, 2024 US11964980
Mail Response to 312 Amendment (PTO-271) 20 Feb, 2024 US11964980
Email Notification 20 Feb, 2024 US11964980


Blueprint Medicines's Family Patents

Blueprint Medicines drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Blueprint Medicines Drug List

Given below is the complete list of Blueprint Medicines's drugs and the patents protecting them.


1. Ayvakit

Ayvakit is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12060354 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making 08 Mar, 2042
(17 years from now)
Active
US11964980 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making 10 Apr, 2040
(15 years from now)
Active
US11999744 Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making 10 Apr, 2040
(15 years from now)
Active
US11827642 Compositions useful for treating disorders related to KIT 15 Oct, 2034
(9 years from now)
Active
US9200002 Compositions useful for treating disorders related to KIT 15 Oct, 2034
(9 years from now)
Active
US9944651 Compositions useful for treating disorders related to kit 15 Oct, 2034
(9 years from now)
Active
US9994575 Compositions useful for treating disorders related to kit 15 Oct, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ayvakit's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Blueprint Medicines News

Ayvakit by Blueprint Medicines: A Promising Solution for Rare-Disease Therapy - BNN Breaking

15 Feb, 2024

Ayvakit peak sales estimate skyrockets to $2B with the help of new blueprint - Fierce Pharma

15 Feb, 2024

See More